(MO) Altria - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US02209S1033
Stock: Cigarettes, Cigars, Smokeless, Nicotine Pouches, E-Vapor
Total Rating 63
Risk 85
Buy Signal -0.44
| Risk 5d forecast | |
|---|---|
| Volatility | 19.3% |
| Relative Tail Risk | -8.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.86 |
| Alpha | 21.63 |
| Character TTM | |
|---|---|
| Beta | -0.083 |
| Beta Downside | -0.093 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.40% |
| CAGR/Max DD | 1.37 |
EPS (Earnings per Share)
Revenue
Description: MO Altria February 26, 2026
Altria Group (NYSE: MO) is a U.S.-based tobacco conglomerate that markets a broad portfolio of smokeable and oral products, including Marlboro cigarettes, Black & Mild cigars, Copenhagen and Skoal smokeless tobacco, the on! nicotine-pouch line, and NJOY ACE e-vapor devices. The company distributes its brands through wholesale partners and major retail chains, leveraging a legacy that dates back to its 1822 founding in Richmond, Virginia.
In the most recent quarter (Q3 2024), Altria posted net revenue of $3.6 billion and adjusted earnings per share of $2.85, reflecting an operating margin of roughly 35%. The firm’s dividend yield remains high at about 8%, while its price-to-earnings multiple hovers near 9×, underscoring the premium income profile that investors often seek in the tobacco sector. Growth is being driven by the on! nicotine-pouch line, which expanded 15% year-over-year, and by continued market share gains in reduced-risk products amid tightening FDA regulations on traditional cigarettes.
For a deeper dive into MO’s valuation, you might explore ValueRay’s analysis.
Headlines to watch out for
- Marlboro cigarette sales remain primary revenue driver
- Regulatory pressure on menthol cigarettes impacts future sales
- Oral tobacco products show growth potential
- Excise taxes and litigation risks persist
- NJOY e-vapor market share expansion crucial for diversification
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 6.95b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 1.43 > 1.0 |
| NWC/Revenue: -17.27% < 20% (prev -20.88%; Δ 3.61% < -1%) |
| CFO/TA 0.27 > 3% & CFO 9.29b > Net Income 6.95b |
| Net Debt (21.23b) to EBITDA (10.70b): 1.98 < 3 |
| Current Ratio: 0.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.68b) vs 12m ago -1.00% < -2% |
| Gross Margin: 69.56% > 18% (prev 0.70%; Δ 6886 % > 0.5%) |
| Asset Turnover: 59.57% > 50% (prev 58.12%; Δ 1.45% > 0%) |
| Interest Coverage Ratio: 9.70 > 6 (EBITDA TTM 10.70b / Interest Expense TTM 1.08b) |
Altman Z'' 6.52
| A: -0.10 (Total Current Assets 5.54b - Total Current Liabilities 9.15b) / Total Assets 35.02b |
| B: 1.01 (Retained Earnings 35.45b / Total Assets 35.02b) |
| C: 0.30 (EBIT TTM 10.47b / Avg Total Assets 35.10b) |
| D: 1.80 (Book Value of Equity 69.21b / Total Liabilities 38.47b) |
| Altman-Z'' Score: 6.52 = AAA |
Beneish M -3.13
| DSRI: 0.95 (Receivables 263.0m/270.0m, Revenue 20.91b/20.44b) |
| GMI: 1.01 (GM 69.56% / 70.27%) |
| AQI: 0.96 (AQ_t 0.79 / AQ_t-1 0.83) |
| SGI: 1.02 (Revenue 20.91b / 20.44b) |
| TATA: -0.07 (NI 6.95b - CFO 9.29b) / TA 35.02b) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of MO shares?
As of March 11, 2026, the stock is trading at USD 67.14 with a total of 6,737,872 shares traded.
Over the past week, the price has changed by -2.54%, over one month by +4.25%, over three months by +16.49% and over the past year by +21.97%.
Over the past week, the price has changed by -2.54%, over one month by +4.25%, over three months by +16.49% and over the past year by +21.97%.
Is MO a buy, sell or hold?
Altria has received a consensus analysts rating of 3.27.
Therefor, it is recommend to hold MO.
- StrongBuy: 3
- Buy: 1
- Hold: 9
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the MO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64.7 | -3.7% |
| Analysts Target Price | 64.7 | -3.7% |
MO Fundamental Data Overview March 07, 2026
P/E Trailing = 16.2573
P/E Forward = 12.1655
P/S = 5.5831
P/B = 25.2407
P/EG = 4.0147
Revenue TTM = 20.91b USD
EBIT TTM = 10.47b USD
EBITDA TTM = 10.70b USD
Long Term Debt = 24.14b USD (from longTermDebt, last quarter)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 25.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.23b USD (from netDebt column, last quarter)
Enterprise Value = 133.67b USD (112.44b + Debt 25.71b - CCE 4.47b)
Interest Coverage Ratio = 9.70 (Ebit TTM 10.47b / Interest Expense TTM 1.08b)
EV/FCF = 14.73x (Enterprise Value 133.67b / FCF TTM 9.07b)
FCF Yield = 6.79% (FCF TTM 9.07b / Enterprise Value 133.67b)
FCF Margin = 43.40% (FCF TTM 9.07b / Revenue TTM 20.91b)
Net Margin = 33.23% (Net Income TTM 6.95b / Revenue TTM 20.91b)
Gross Margin = 69.56% ((Revenue TTM 20.91b - Cost of Revenue TTM 6.36b) / Revenue TTM)
Gross Margin QoQ = 62.11% (prev 72.60%)
Tobins Q-Ratio = 3.82 (Enterprise Value 133.67b / Total Assets 35.02b)
Interest Expense / Debt = 1.03% (Interest Expense 264.0m / Debt 25.71b)
Taxrate = 26.17% (396.0m / 1.51b)
NOPAT = 7.73b (EBIT 10.47b * (1 - 26.17%))
Current Ratio = 0.61 (Total Current Assets 5.54b / Total Current Liabilities 9.15b)
Debt / Equity = -7.34 (negative equity) (Debt 25.71b / totalStockholderEquity, last quarter -3.50b)
Debt / EBITDA = 1.98 (Net Debt 21.23b / EBITDA 10.70b)
Debt / FCF = 2.34 (Net Debt 21.23b / FCF TTM 9.07b)
Total Stockholder Equity = -3.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.79% (Net Income 6.95b / Total Assets 35.02b)
RoE = -215.2% (negative equity) (Net Income TTM 6.95b / Total Stockholder Equity -3.23b)
RoCE = 50.06% (EBIT 10.47b / Capital Employed (Equity -3.23b + L.T.Debt 24.14b))
RoIC = 34.57% (NOPAT 7.73b / Invested Capital 22.36b)
WACC = 4.71% (E(112.44b)/V(138.15b) * Re(5.61%) + D(25.71b)/V(138.15b) * Rd(1.03%) * (1-Tc(0.26)))
Discount Rate = 5.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.61%
[DCF] Terminal Value 86.69% ; FCFF base≈8.89b ; Y1≈9.22b ; Y5≈10.49b
[DCF] Fair Price = 173.5 (EV 311.76b - Net Debt 21.23b = Equity 290.53b / Shares 1.67b; r=5.90% [WACC]; 5y FCF grow 3.86% → 2.90% )
EPS Correlation: 60.03 | EPS CAGR: 4.05% | SUE: -0.36 | # QB: 0
Revenue Correlation: 17.35 | Revenue CAGR: 5.29% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.47 | Chg7d=+0.005 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=11
EPS current Year (2026-12-31): EPS=5.62 | Chg7d=+0.032 | Chg30d=+0.028 | Revisions Net=+0 | Growth EPS=+3.6% | Growth Revenue=+0.6%
EPS next Year (2027-12-31): EPS=5.81 | Chg7d=+0.011 | Chg30d=+0.012 | Revisions Net=+3 | Growth EPS=+3.5% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.8% (Discount Rate 7.9% - Earnings Yield 6.2%)
[Growth] Growth Spread = -1.6% (Analyst 0.2% - Implied 1.8%)
P/E Forward = 12.1655
P/S = 5.5831
P/B = 25.2407
P/EG = 4.0147
Revenue TTM = 20.91b USD
EBIT TTM = 10.47b USD
EBITDA TTM = 10.70b USD
Long Term Debt = 24.14b USD (from longTermDebt, last quarter)
Short Term Debt = 1.57b USD (from shortTermDebt, last quarter)
Debt = 25.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 21.23b USD (from netDebt column, last quarter)
Enterprise Value = 133.67b USD (112.44b + Debt 25.71b - CCE 4.47b)
Interest Coverage Ratio = 9.70 (Ebit TTM 10.47b / Interest Expense TTM 1.08b)
EV/FCF = 14.73x (Enterprise Value 133.67b / FCF TTM 9.07b)
FCF Yield = 6.79% (FCF TTM 9.07b / Enterprise Value 133.67b)
FCF Margin = 43.40% (FCF TTM 9.07b / Revenue TTM 20.91b)
Net Margin = 33.23% (Net Income TTM 6.95b / Revenue TTM 20.91b)
Gross Margin = 69.56% ((Revenue TTM 20.91b - Cost of Revenue TTM 6.36b) / Revenue TTM)
Gross Margin QoQ = 62.11% (prev 72.60%)
Tobins Q-Ratio = 3.82 (Enterprise Value 133.67b / Total Assets 35.02b)
Interest Expense / Debt = 1.03% (Interest Expense 264.0m / Debt 25.71b)
Taxrate = 26.17% (396.0m / 1.51b)
NOPAT = 7.73b (EBIT 10.47b * (1 - 26.17%))
Current Ratio = 0.61 (Total Current Assets 5.54b / Total Current Liabilities 9.15b)
Debt / Equity = -7.34 (negative equity) (Debt 25.71b / totalStockholderEquity, last quarter -3.50b)
Debt / EBITDA = 1.98 (Net Debt 21.23b / EBITDA 10.70b)
Debt / FCF = 2.34 (Net Debt 21.23b / FCF TTM 9.07b)
Total Stockholder Equity = -3.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 19.79% (Net Income 6.95b / Total Assets 35.02b)
RoE = -215.2% (negative equity) (Net Income TTM 6.95b / Total Stockholder Equity -3.23b)
RoCE = 50.06% (EBIT 10.47b / Capital Employed (Equity -3.23b + L.T.Debt 24.14b))
RoIC = 34.57% (NOPAT 7.73b / Invested Capital 22.36b)
WACC = 4.71% (E(112.44b)/V(138.15b) * Re(5.61%) + D(25.71b)/V(138.15b) * Rd(1.03%) * (1-Tc(0.26)))
Discount Rate = 5.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.61%
[DCF] Terminal Value 86.69% ; FCFF base≈8.89b ; Y1≈9.22b ; Y5≈10.49b
[DCF] Fair Price = 173.5 (EV 311.76b - Net Debt 21.23b = Equity 290.53b / Shares 1.67b; r=5.90% [WACC]; 5y FCF grow 3.86% → 2.90% )
EPS Correlation: 60.03 | EPS CAGR: 4.05% | SUE: -0.36 | # QB: 0
Revenue Correlation: 17.35 | Revenue CAGR: 5.29% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.47 | Chg7d=+0.005 | Chg30d=+0.000 | Revisions Net=-2 | Analysts=11
EPS current Year (2026-12-31): EPS=5.62 | Chg7d=+0.032 | Chg30d=+0.028 | Revisions Net=+0 | Growth EPS=+3.6% | Growth Revenue=+0.6%
EPS next Year (2027-12-31): EPS=5.81 | Chg7d=+0.011 | Chg30d=+0.012 | Revisions Net=+3 | Growth EPS=+3.5% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.8% (Discount Rate 7.9% - Earnings Yield 6.2%)
[Growth] Growth Spread = -1.6% (Analyst 0.2% - Implied 1.8%)